FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for KYPROLIS (carfilzomib) submitted by Onyx Pharmaceuticals, expanding the label and/or indications for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Kyprolis (carfilzomib)

Snippet

SUPPL AP for KYPROLIS (CARFILZOMIB)